(c)

	Edema (% recipients)	Wound complications (% recipients)	Ulcers (% recipients)	Bile duct complications (% recipients)	Infections (% recipients)	Dermatological effects (% recipients)	Hematological effects (% recipients)
De novo dosing
Levy et al. Liver Transpl. 2006; 12: 1640–8 [52]					CMV disease: 3.3, 3.6, 6.7, and 9.7 (placebo versus EVR 1, 2, and 4 mg/day, respectively, P = NS for all comparisons)		Thrombocytopenia: 10.0, 14.3, 20.0, and 19.4 Leukopenia: 0, 14.3, 6.7, and 6.5 (placebo, EVR 1, 2, and 4 mg/day, PS = NS for all comparisons)
Early conversion (≤3 months after transplantation)
De Simone et al. Am J Transplant. 2012; 12: 3008–20 [87]	17.6 versus 10.8 (EVR + TAC-RD versus TAC-SD, RR 1.63, 95% CI 1.03, 2.56)	Wound complications: 11.0 versus 7.9 (EVR + TAC-RD versus TAC-SD, RR 1.40, 95% CI 0.80, 2.45) Incisional hernia: 2.9 versus 1.2 (RR 2.30, 95% CI, 0.60, 8.77)					Leukopenia: 11.8 versus 5.0 (EVR + TAC-RD versus TAC-SD, RR 2.38, 95% CI 1.24, 4.55) Thrombocytopenia: 5.3 versus 1.7 Anemia: 7.8 versus 8.3 (EVR + TAC-RD versus TAC-SD, RR 0.93, 95% CI 0.51, 1.71)
Fischer et al. Am J Transplant. 2012; 12: 1855–65 [50]		Wound complications: 2 versus 3.9 Incisional hernia: 11.9 versus 9.8 Wound dehiscence: 0 versus 1 Wound hemorrhage: 1 versus 0 (all EVR versus CNI)			Infections and infestations: 73.3 versus 59.8 (EVR versus CNI)		Anemia: 18.8 versus 10.8 Leukopenia: 20.8 versus 9.8*  Thrombocytopenia: 7.9 versus 6.9 (all EVR versus CNI, P = NS for anemia and thrombocytopenia)
Masetti et al. Am J Transplant. 2010; 10: 2252–62 [89]	Inferior limb edema: 9.6 versus 0 (EVR versus CsA, P = NS)	Incisional hernia: 46.1 versus 26.9 (EVR versus CsA, P = NS)		Biliary complications (stenosis/leak): 21.1 versus 30.8 (EVR versus CsA, P = NS)	Infections: 46.1 versus 46.1 (EVR versus CsA, P = NS) CMV: 19.2 versus 23.1 (EVR versus CsA, P = NS)
Late conversion (>3 months after transplantation)
Bilbao et al. Transplant Proc. 2009; 41: 2172–6 [92]			Mucositis: 4		Sepsis in the context of graft-versus-host disease: 4
Casanovas et al. Transplant Proc. 2011; 43: 2216–9 [93]							Anemia, leukopenia, and thrombocytopenia: 11.4
De Simone et al. Transpl Int. 2009; 22: 279–86 [95]			Oral ulcers/stomatitis: 22.5		Lower urinary tract infection: 5	Pruritis and acne: 7.5
De Simone et al. Liver Transpl. 2009; 15: 1262–9 [96]			Mouth ulcers: 26.4 versus 0.0 (EVR versus SNI, P < 0.01)		Infections: 31.9 versus 21.9, of which 15.3 versus 1.4 were suspected to be drug-related (EVR versus CNI)	Rash/dry skin/eczema: 6.9 versus 0.0 (EVR versus CNI, P = 0.028)	Leukopenia: 12.5 versus 5.5 Thrombocytopenia: 5.6 versus 1.4 Anemia: 9.7 versus 4.1 (all EVR versus CNI)
Saliba et al. Liver Transpl. 2011; 17: 905–13 [98]	Edema: 16.3		Stomatitis/mouth ulcers: 14.2		Bacterial infection: 12.5	Rash: 18.8	Anemia: 12.9 Leukopenia: 9.2 Thrombocytopenia: 6.3
Vallin et al. Clin Transplant. 2011; 25: 660–9 [99]	Edema: 7		Mucositis: 15		Infection: 3	Dermatitis: 19

CMV: cytomegalovirus; CNI: calcineurin inhibitor; CsA: cyclosporine A; EVR: everolimus; NS: nonsignificant; SRL: sirolimus; RR: relative risk; 95% CI: 95% confidence interval; TAC: tacrolimus; TAC-RD: reduced-dose tacrolimus (C0: 3–5 ng/mL); TAC-SD: standard-dose tacrolimus (C0: 6–10 ng/mL).

P values are included where available *Treatment group differences with an exploratory P value of P ≤ 0.05.